UBS Group AG Has $3.67 Million Stock Holdings in Sionna Therapeutics, Inc. $SION

UBS Group AG raised its holdings in Sionna Therapeutics, Inc. (NASDAQ:SION) by 91.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 89,177 shares of the company’s stock after purchasing an additional 42,511 shares during the quarter. UBS Group AG’s holdings in Sionna Therapeutics were worth $3,669,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. Bank of America Corp DE boosted its holdings in shares of Sionna Therapeutics by 8.8% in the 3rd quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock valued at $192,000 after purchasing an additional 529 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Sionna Therapeutics by 35.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Sionna Therapeutics in the 4th quarter valued at $36,000. Russell Investments Group Ltd. acquired a new stake in shares of Sionna Therapeutics in the 3rd quarter valued at $30,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Sionna Therapeutics in the 4th quarter valued at $89,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Lifesci Capital raised Sionna Therapeutics to a “strong-buy” rating in a report on Wednesday, February 25th. Freedom Capital downgraded Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Guggenheim raised their target price on Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Monday, March 2nd. UBS Group reaffirmed a “buy” rating on shares of Sionna Therapeutics in a report on Monday, March 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Friday, May 8th. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $53.22.

Sionna Therapeutics Stock Down 1.5%

Shares of NASDAQ:SION opened at $41.13 on Friday. The firm has a market cap of $1.86 billion, a P/E ratio of -21.31 and a beta of 1.35. Sionna Therapeutics, Inc. has a 12-month low of $12.42 and a 12-month high of $48.44. The business has a fifty day simple moving average of $39.69 and a 200 day simple moving average of $39.59.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.08). As a group, equities research analysts expect that Sionna Therapeutics, Inc. will post -2.57 EPS for the current year.

Insider Buying and Selling at Sionna Therapeutics

In related news, Director Orbimed Advisors Llc sold 235,863 shares of the firm’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the completion of the transaction, the director directly owned 3,247,025 shares of the company’s stock, valued at $144,947,196. This trade represents a 6.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 235,863 shares of the firm’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares of the company’s stock, valued at approximately $144,947,196. This represents a 6.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,717,760 shares of company stock valued at $77,562,902. 3.90% of the stock is owned by corporate insiders.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.